RU2001129155A - Соединения с арильными заместителями (варианты), фармацевтическая композиция и способ лечения расстройства, чувствительного к блокаде натриевых каналов у млекопитающего, способ лечения, профилактики различных заболеваний или уменьшения интенсивности гибели или потери нейронов (варианты), способ облегчения или предупреждения эпилептических припадков у животного (варианты), соединение - радиоактивный лиганд для участка связывания в натриевом канале - Google Patents
Соединения с арильными заместителями (варианты), фармацевтическая композиция и способ лечения расстройства, чувствительного к блокаде натриевых каналов у млекопитающего, способ лечения, профилактики различных заболеваний или уменьшения интенсивности гибели или потери нейронов (варианты), способ облегчения или предупреждения эпилептических припадков у животного (варианты), соединение - радиоактивный лиганд для участка связывания в натриевом канале Download PDFInfo
- Publication number
- RU2001129155A RU2001129155A RU2001129155/04A RU2001129155A RU2001129155A RU 2001129155 A RU2001129155 A RU 2001129155A RU 2001129155/04 A RU2001129155/04 A RU 2001129155/04A RU 2001129155 A RU2001129155 A RU 2001129155A RU 2001129155 A RU2001129155 A RU 2001129155A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- group
- hydrogen
- phenyl
- amino
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 50
- 125000003118 aryl group Chemical group 0.000 title claims 31
- 238000000034 method Methods 0.000 title claims 10
- 241000124008 Mammalia Species 0.000 title claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 6
- 206010010904 Convulsion Diseases 0.000 title claims 5
- 241001465754 Metazoa Species 0.000 title claims 5
- 108010052164 Sodium Channels Proteins 0.000 title claims 5
- 102000018674 Sodium Channels Human genes 0.000 title claims 5
- 230000002285 radioactive effect Effects 0.000 title claims 3
- 239000003446 ligand Substances 0.000 title claims 2
- 210000002569 neuron Anatomy 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 230000003247 decreasing effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 70
- 239000001257 hydrogen Substances 0.000 claims 56
- 125000000217 alkyl group Chemical group 0.000 claims 54
- -1 cyano, amino Chemical group 0.000 claims 53
- 150000002431 hydrogen Chemical class 0.000 claims 50
- 125000001424 substituent group Chemical group 0.000 claims 37
- 125000000753 cycloalkyl group Chemical group 0.000 claims 33
- 125000003342 alkenyl group Chemical group 0.000 claims 28
- 125000000304 alkynyl group Chemical group 0.000 claims 28
- 125000001072 heteroaryl group Chemical group 0.000 claims 28
- 125000000623 heterocyclic group Chemical group 0.000 claims 25
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 22
- 229910052760 oxygen Inorganic materials 0.000 claims 22
- 125000004103 aminoalkyl group Chemical group 0.000 claims 20
- 125000001188 haloalkyl group Chemical group 0.000 claims 20
- 229910052717 sulfur Inorganic materials 0.000 claims 20
- 125000003282 alkyl amino group Chemical group 0.000 claims 19
- 125000003545 alkoxy group Chemical group 0.000 claims 18
- 125000003710 aryl alkyl group Chemical group 0.000 claims 18
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 18
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 17
- 125000004432 carbon atom Chemical group C* 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 15
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims 14
- 150000002367 halogens Chemical class 0.000 claims 14
- 125000005018 aryl alkenyl group Chemical group 0.000 claims 13
- 125000005015 aryl alkynyl group Chemical group 0.000 claims 13
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 12
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 12
- 125000004663 dialkyl amino group Chemical group 0.000 claims 12
- 125000000547 substituted alkyl group Chemical group 0.000 claims 12
- 150000001356 alkyl thiols Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 10
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 10
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 239000000651 prodrug Substances 0.000 claims 10
- 229940002612 prodrug Drugs 0.000 claims 10
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 9
- 125000006323 alkenyl amino group Chemical group 0.000 claims 9
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 9
- 125000004414 alkyl thio group Chemical group 0.000 claims 9
- 125000005126 aryl alkyl carbonyl amino group Chemical group 0.000 claims 9
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 229910052783 alkali metal Inorganic materials 0.000 claims 8
- 150000001340 alkali metals Chemical class 0.000 claims 8
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 8
- 125000005125 aryl alkyl amino carbonyl group Chemical group 0.000 claims 8
- 150000003573 thiols Chemical class 0.000 claims 8
- 150000001408 amides Chemical class 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 208000002193 Pain Diseases 0.000 claims 6
- 125000004442 acylamino group Chemical group 0.000 claims 6
- 125000004423 acyloxy group Chemical group 0.000 claims 6
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 5
- 125000004447 heteroarylalkenyl group Chemical group 0.000 claims 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 5
- 125000005312 heteroarylalkynyl group Chemical group 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 230000036407 pain Effects 0.000 claims 5
- 229920006395 saturated elastomer Polymers 0.000 claims 5
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 3
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 208000009205 Tinnitus Diseases 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- 208000028683 bipolar I disease Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 238000002690 local anesthesia Methods 0.000 claims 2
- 230000000626 neurodegenerative effect Effects 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 231100000886 tinnitus Toxicity 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 claims 1
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 1
- VKBOFLKFVJNVON-UHFFFAOYSA-N 1-[3-[4-(4-nitrophenoxy)phenyl]pyrazol-1-yl]ethanone Chemical compound CC(=O)N1C=CC(C=2C=CC(OC=3C=CC(=CC=3)[N+]([O-])=O)=CC=2)=N1 VKBOFLKFVJNVON-UHFFFAOYSA-N 0.000 claims 1
- JUTGEKQFBMEDCR-UHFFFAOYSA-N 1-[5-[4-(4-fluorophenoxy)phenyl]pyrazol-1-yl]-2-methylpropan-2-ol Chemical compound CC(C)(O)CN1N=CC=C1C(C=C1)=CC=C1OC1=CC=C(F)C=C1 JUTGEKQFBMEDCR-UHFFFAOYSA-N 0.000 claims 1
- CIOBKBATFFYLPA-UHFFFAOYSA-N 1-[5-[4-(4-fluorophenoxy)phenyl]pyrazol-1-yl]propan-2-one Chemical compound CC(=O)CN1N=CC=C1C(C=C1)=CC=C1OC1=CC=C(F)C=C1 CIOBKBATFFYLPA-UHFFFAOYSA-N 0.000 claims 1
- LFABDKAVGRGBKB-UHFFFAOYSA-N 1-benzyl-5-[4-(4-fluorophenoxy)phenyl]pyrazole Chemical compound C1=CC(F)=CC=C1OC1=CC=C(C=2N(N=CC=2)CC=2C=CC=CC=2)C=C1 LFABDKAVGRGBKB-UHFFFAOYSA-N 0.000 claims 1
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims 1
- LJWPODFBXNZRNJ-UHFFFAOYSA-N 2-[3-[4-(4-fluorophenoxy)phenyl]pyrazol-1-yl]acetamide Chemical compound NC(=O)CN1C=CC(C=2C=CC(OC=3C=CC(F)=CC=3)=CC=2)=N1 LJWPODFBXNZRNJ-UHFFFAOYSA-N 0.000 claims 1
- PAQCDHCQXZZOTK-UHFFFAOYSA-N 2-[3-[4-(4-fluorophenoxy)phenyl]pyrazol-1-yl]pyrimidine Chemical compound C1=CC(F)=CC=C1OC1=CC=C(C2=NN(C=C2)C=2N=CC=CN=2)C=C1 PAQCDHCQXZZOTK-UHFFFAOYSA-N 0.000 claims 1
- BIWLLWXBQCQLGG-UHFFFAOYSA-N 2-[3-[4-[4-(trifluoromethyl)phenoxy]phenyl]pyrazol-1-yl]pyrimidine Chemical compound C1=CC(C(F)(F)F)=CC=C1OC1=CC=C(C2=NN(C=C2)C=2N=CC=CN=2)C=C1 BIWLLWXBQCQLGG-UHFFFAOYSA-N 0.000 claims 1
- RYBGVNFVNQDALX-UHFFFAOYSA-N 2-[4-(4-fluorophenoxy)phenyl]-1,3-oxazole-4-carboxamide Chemical compound NC(=O)C1=COC(C=2C=CC(OC=3C=CC(F)=CC=3)=CC=2)=N1 RYBGVNFVNQDALX-UHFFFAOYSA-N 0.000 claims 1
- DNGUPPLQAHDYIP-UHFFFAOYSA-N 2-[4-(4-fluorophenoxy)phenyl]-1h-benzimidazole Chemical compound C1=CC(F)=CC=C1OC1=CC=C(C=2NC3=CC=CC=C3N=2)C=C1 DNGUPPLQAHDYIP-UHFFFAOYSA-N 0.000 claims 1
- PMYHGIHNTWYDPH-UHFFFAOYSA-N 2-[4-(4-fluorophenoxy)phenyl]-1h-imidazole Chemical compound C1=CC(F)=CC=C1OC1=CC=C(C=2NC=CN=2)C=C1 PMYHGIHNTWYDPH-UHFFFAOYSA-N 0.000 claims 1
- CSSAKNGWMRWKCM-UHFFFAOYSA-N 2-[4-(4-fluorophenoxy)phenyl]-1h-imidazole-5-carbonitrile Chemical compound C1=CC(F)=CC=C1OC1=CC=C(C=2NC=C(N=2)C#N)C=C1 CSSAKNGWMRWKCM-UHFFFAOYSA-N 0.000 claims 1
- XBMSSDWJDPMMOF-UHFFFAOYSA-N 2-[4-(4-fluorophenoxy)phenyl]-1h-imidazole-5-carboxamide Chemical compound NC(=O)C1=CNC(C=2C=CC(OC=3C=CC(F)=CC=3)=CC=2)=N1 XBMSSDWJDPMMOF-UHFFFAOYSA-N 0.000 claims 1
- ABCFFRHJLNZMLK-UHFFFAOYSA-N 2-[5-[4-(4-fluorophenoxy)phenyl]pyrazol-1-yl]-1-morpholin-4-ylethanone Chemical compound C1=CC(F)=CC=C1OC1=CC=C(C=2N(N=CC=2)CC(=O)N2CCOCC2)C=C1 ABCFFRHJLNZMLK-UHFFFAOYSA-N 0.000 claims 1
- KDGBSQOBDISXJY-UHFFFAOYSA-N 2-[5-[4-(4-fluorophenoxy)phenyl]pyrazol-1-yl]-1-pyrrolidin-1-ylethanone Chemical compound C1=CC(F)=CC=C1OC1=CC=C(C=2N(N=CC=2)CC(=O)N2CCCC2)C=C1 KDGBSQOBDISXJY-UHFFFAOYSA-N 0.000 claims 1
- JGJHKOJSLNYHPK-UHFFFAOYSA-N 2-[5-[4-(4-fluorophenoxy)phenyl]pyrazol-1-yl]acetamide Chemical compound NC(=O)CN1N=CC=C1C(C=C1)=CC=C1OC1=CC=C(F)C=C1 JGJHKOJSLNYHPK-UHFFFAOYSA-N 0.000 claims 1
- QGYHMLTWZSJCMM-UHFFFAOYSA-N 2-[5-[4-(4-fluorophenoxy)phenyl]pyrazol-1-yl]ethanol Chemical compound OCCN1N=CC=C1C(C=C1)=CC=C1OC1=CC=C(F)C=C1 QGYHMLTWZSJCMM-UHFFFAOYSA-N 0.000 claims 1
- SFXMKTZKDUFZLC-UHFFFAOYSA-N 2-[5-[4-(4-fluorophenoxy)phenyl]pyrazol-1-yl]ethyl carbamate Chemical compound NC(=O)OCCN1N=CC=C1C(C=C1)=CC=C1OC1=CC=C(F)C=C1 SFXMKTZKDUFZLC-UHFFFAOYSA-N 0.000 claims 1
- FTVGTSUFLFFSDY-UHFFFAOYSA-N 3-(4-phenoxyphenyl)pyrazole-1-carboxamide Chemical compound NC(=O)N1C=CC(C=2C=CC(OC=3C=CC=CC=3)=CC=2)=N1 FTVGTSUFLFFSDY-UHFFFAOYSA-N 0.000 claims 1
- PVIJYBAGFROCOB-UHFFFAOYSA-N 3-[3-fluoro-4-(4-fluorophenoxy)phenyl]pyrazole-1-carboxamide Chemical compound NC(=O)N1C=CC(C=2C=C(F)C(OC=3C=CC(F)=CC=3)=CC=2)=N1 PVIJYBAGFROCOB-UHFFFAOYSA-N 0.000 claims 1
- OYOZIANRHNFTPI-UHFFFAOYSA-N 3-[4-(2,4-difluorophenoxy)phenyl]pyrazole-1-carboxamide Chemical compound NC(=O)N1C=CC(C=2C=CC(OC=3C(=CC(F)=CC=3)F)=CC=2)=N1 OYOZIANRHNFTPI-UHFFFAOYSA-N 0.000 claims 1
- DWURZDHXVIRXAE-UHFFFAOYSA-N 3-[4-(2-chloro-4-fluorophenoxy)phenyl]pyrazole-1-carboxamide Chemical compound NC(=O)N1C=CC(C=2C=CC(OC=3C(=CC(F)=CC=3)Cl)=CC=2)=N1 DWURZDHXVIRXAE-UHFFFAOYSA-N 0.000 claims 1
- PTUJSDGCLJXZRN-UHFFFAOYSA-N 3-[4-(3-chloro-2-cyanophenoxy)phenyl]pyrazole-1-carboxamide Chemical compound NC(=O)N1C=CC(C=2C=CC(OC=3C(=C(Cl)C=CC=3)C#N)=CC=2)=N1 PTUJSDGCLJXZRN-UHFFFAOYSA-N 0.000 claims 1
- VICKOKAOSUOGIB-UHFFFAOYSA-N 3-[4-(4-aminophenoxy)phenyl]pyrazole-1-carboxamide Chemical compound NC(=O)N1C=CC(C=2C=CC(OC=3C=CC(N)=CC=3)=CC=2)=N1 VICKOKAOSUOGIB-UHFFFAOYSA-N 0.000 claims 1
- ITAWDKBZOLCQET-UHFFFAOYSA-N 3-[4-(4-chloro-2-fluorophenoxy)phenyl]pyrazole-1-carboxamide Chemical compound NC(=O)N1C=CC(C=2C=CC(OC=3C(=CC(Cl)=CC=3)F)=CC=2)=N1 ITAWDKBZOLCQET-UHFFFAOYSA-N 0.000 claims 1
- RZSLUTWLYXWUSF-UHFFFAOYSA-N 3-[4-(4-cyanophenoxy)phenyl]pyrazole-1-carboxamide Chemical compound NC(=O)N1C=CC(C=2C=CC(OC=3C=CC(=CC=3)C#N)=CC=2)=N1 RZSLUTWLYXWUSF-UHFFFAOYSA-N 0.000 claims 1
- YNTRUANMLCUDBZ-UHFFFAOYSA-N 3-[4-(4-fluorophenoxy)phenyl]-n,n-dimethylpyrazole-1-carboxamide Chemical compound CN(C)C(=O)N1C=CC(C=2C=CC(OC=3C=CC(F)=CC=3)=CC=2)=N1 YNTRUANMLCUDBZ-UHFFFAOYSA-N 0.000 claims 1
- MRGZCLZDYCRVKL-UHFFFAOYSA-N 3-[4-(4-fluorophenoxy)phenyl]pyrazole-1-carboxamide Chemical compound NC(=O)N1C=CC(C=2C=CC(OC=3C=CC(F)=CC=3)=CC=2)=N1 MRGZCLZDYCRVKL-UHFFFAOYSA-N 0.000 claims 1
- CJNZUOYYPQXPIJ-UHFFFAOYSA-N 3-[4-(4-fluorophenyl)sulfanylphenyl]pyrazole-1-carboxamide Chemical compound NC(=O)N1C=CC(C=2C=CC(SC=3C=CC(F)=CC=3)=CC=2)=N1 CJNZUOYYPQXPIJ-UHFFFAOYSA-N 0.000 claims 1
- DNSIJBDKAVUAKO-UHFFFAOYSA-N 3-[4-(4-methoxyphenoxy)phenyl]pyrazole-1-carboxamide Chemical compound C1=CC(OC)=CC=C1OC1=CC=C(C2=NN(C=C2)C(N)=O)C=C1 DNSIJBDKAVUAKO-UHFFFAOYSA-N 0.000 claims 1
- TXAVIYCBJUQLRV-UHFFFAOYSA-N 3-[4-(4-nitrophenoxy)phenyl]pyrazole-1-carboxamide Chemical compound NC(=O)N1C=CC(C=2C=CC(OC=3C=CC(=CC=3)[N+]([O-])=O)=CC=2)=N1 TXAVIYCBJUQLRV-UHFFFAOYSA-N 0.000 claims 1
- WZVXAXUFPJMFAC-UHFFFAOYSA-N 3-[5-[4-(4-fluorophenoxy)phenyl]pyrazol-1-yl]propanamide Chemical compound NC(=O)CCN1N=CC=C1C(C=C1)=CC=C1OC1=CC=C(F)C=C1 WZVXAXUFPJMFAC-UHFFFAOYSA-N 0.000 claims 1
- NWOICISHTNVGPI-UHFFFAOYSA-N 4-[4-(2,4-difluorophenoxy)phenyl]-1-methylimidazole-2-carboxamide Chemical compound N1=C(C(N)=O)N(C)C=C1C(C=C1)=CC=C1OC1=CC=C(F)C=C1F NWOICISHTNVGPI-UHFFFAOYSA-N 0.000 claims 1
- NFXDWZKZVQNAAI-UHFFFAOYSA-N 5-[3-fluoro-4-(4-fluorophenoxy)phenyl]-1h-imidazole Chemical compound C1=CC(F)=CC=C1OC1=CC=C(C=2N=CNC=2)C=C1F NFXDWZKZVQNAAI-UHFFFAOYSA-N 0.000 claims 1
- KIAHCCWSNXBWDQ-UHFFFAOYSA-N 5-[4-(2,4-difluorophenoxy)phenyl]-1h-imidazole Chemical compound FC1=CC(F)=CC=C1OC1=CC=C(C=2N=CNC=2)C=C1 KIAHCCWSNXBWDQ-UHFFFAOYSA-N 0.000 claims 1
- DIHPDGVREOKWAX-UHFFFAOYSA-N 5-[4-(2,4-difluorophenoxy)phenyl]-2-methyl-1h-imidazole Chemical compound N1C(C)=NC(C=2C=CC(OC=3C(=CC(F)=CC=3)F)=CC=2)=C1 DIHPDGVREOKWAX-UHFFFAOYSA-N 0.000 claims 1
- RRBDNNKATHQXSL-UHFFFAOYSA-N 5-[4-(4-chloro-2-fluorophenoxy)phenyl]-1h-imidazole Chemical compound FC1=CC(Cl)=CC=C1OC1=CC=C(C=2N=CNC=2)C=C1 RRBDNNKATHQXSL-UHFFFAOYSA-N 0.000 claims 1
- FMGBXNGBWPWGEK-UHFFFAOYSA-N 5-[4-(4-fluorophenoxy)phenyl]-1h-imidazole Chemical compound C1=CC(F)=CC=C1OC1=CC=C(C=2N=CNC=2)C=C1 FMGBXNGBWPWGEK-UHFFFAOYSA-N 0.000 claims 1
- CGMPMLHCCFCLQL-UHFFFAOYSA-N 5-[4-(4-fluorophenoxy)phenyl]-1h-pyrazole Chemical compound C1=CC(F)=CC=C1OC1=CC=C(C2=NNC=C2)C=C1 CGMPMLHCCFCLQL-UHFFFAOYSA-N 0.000 claims 1
- UCKUGEJNUBWWMS-UHFFFAOYSA-N 5-[4-(4-fluorophenyl)sulfanylphenyl]-1h-pyrazole Chemical compound C1=CC(F)=CC=C1SC1=CC=C(C2=NNC=C2)C=C1 UCKUGEJNUBWWMS-UHFFFAOYSA-N 0.000 claims 1
- XXNVJVIBKMMONX-UHFFFAOYSA-N 5-[4-[4-(trifluoromethyl)phenoxy]phenyl]-1h-imidazole Chemical compound C1=CC(C(F)(F)F)=CC=C1OC1=CC=C(C=2N=CNC=2)C=C1 XXNVJVIBKMMONX-UHFFFAOYSA-N 0.000 claims 1
- GWGLECLUOBAWQJ-UHFFFAOYSA-N 5-methylsulfanyl-3-(4-phenoxyphenyl)pyrazole-1-carboxamide Chemical compound NC(=O)N1C(SC)=CC(C=2C=CC(OC=3C=CC=CC=3)=CC=2)=N1 GWGLECLUOBAWQJ-UHFFFAOYSA-N 0.000 claims 1
- IIFSJFXZWQFZER-UHFFFAOYSA-N 5-methylsulfinyl-3-(4-phenoxyphenyl)pyrazole-1-carboxamide Chemical compound NC(=O)N1C(S(=O)C)=CC(C=2C=CC(OC=3C=CC=CC=3)=CC=2)=N1 IIFSJFXZWQFZER-UHFFFAOYSA-N 0.000 claims 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- LOPGZBCUMUNSFM-UHFFFAOYSA-N methyl 5-[4-(4-fluorophenoxy)phenyl]-1h-pyrrole-2-carboxylate Chemical compound N1C(C(=O)OC)=CC=C1C(C=C1)=CC=C1OC1=CC=C(F)C=C1 LOPGZBCUMUNSFM-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- AYFUNGMLUBOVCL-UHFFFAOYSA-N n-[2-[5-[4-(4-fluorophenoxy)phenyl]pyrazol-1-yl]ethyl]methanesulfonamide Chemical compound CS(=O)(=O)NCCN1N=CC=C1C(C=C1)=CC=C1OC1=CC=C(F)C=C1 AYFUNGMLUBOVCL-UHFFFAOYSA-N 0.000 claims 1
- VKMFZYMRPXMJHH-UHFFFAOYSA-N n-[5-[4-(4-fluorophenoxy)phenyl]pyrazol-1-yl]-n-methylacetamide Chemical compound CC(=O)N(C)N1N=CC=C1C(C=C1)=CC=C1OC1=CC=C(F)C=C1 VKMFZYMRPXMJHH-UHFFFAOYSA-N 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000016273 neuron death Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 1
- 0 *c1c(*)c(C*CC(C=*)c2c(*3)c(*)c(*)c(*)c2*)c3c(*)c1* Chemical compound *c1c(*)c(C*CC(C=*)c2c(*3)c(*)c(*)c(*)c2*)c3c(*)c1* 0.000 description 8
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12655399P | 1999-03-26 | 1999-03-26 | |
| US60/126,553 | 1999-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2001129155A true RU2001129155A (ru) | 2003-08-10 |
Family
ID=22425462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2001129155/04A RU2001129155A (ru) | 1999-03-26 | 2000-03-24 | Соединения с арильными заместителями (варианты), фармацевтическая композиция и способ лечения расстройства, чувствительного к блокаде натриевых каналов у млекопитающего, способ лечения, профилактики различных заболеваний или уменьшения интенсивности гибели или потери нейронов (варианты), способ облегчения или предупреждения эпилептических припадков у животного (варианты), соединение - радиоактивный лиганд для участка связывания в натриевом канале |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US6414011B1 (enExample) |
| EP (2) | EP1173169B1 (enExample) |
| JP (2) | JP4832647B2 (enExample) |
| KR (1) | KR20020015308A (enExample) |
| CN (1) | CN1353605A (enExample) |
| AR (1) | AR023171A1 (enExample) |
| AT (1) | ATE467620T1 (enExample) |
| AU (1) | AU782353B2 (enExample) |
| BR (1) | BR0009322A (enExample) |
| CA (1) | CA2368631A1 (enExample) |
| CY (1) | CY1111163T1 (enExample) |
| CZ (1) | CZ20013435A3 (enExample) |
| DE (2) | DE20080291U1 (enExample) |
| DK (1) | DK1173169T3 (enExample) |
| ES (1) | ES2345921T3 (enExample) |
| HU (1) | HUP0201314A3 (enExample) |
| IL (1) | IL145508A0 (enExample) |
| MX (1) | MXPA01009655A (enExample) |
| NO (1) | NO20014659L (enExample) |
| NZ (2) | NZ514756A (enExample) |
| PL (1) | PL351439A1 (enExample) |
| PT (1) | PT1173169E (enExample) |
| RU (1) | RU2001129155A (enExample) |
| TR (1) | TR200102790T2 (enExample) |
| TW (1) | TW502019B (enExample) |
| UA (1) | UA72244C2 (enExample) |
| WO (1) | WO2000057877A1 (enExample) |
| YU (1) | YU68701A (enExample) |
| ZA (1) | ZA200108807B (enExample) |
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7517880B2 (en) * | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| ES2384160T3 (es) | 1999-01-13 | 2012-07-02 | Bayer Healthcare Llc | Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38 |
| WO2000061188A1 (en) * | 1999-04-09 | 2000-10-19 | Euro-Celtique S.A. | Sodium channel blocker compositions and the use thereof |
| TWI283577B (en) * | 1999-10-11 | 2007-07-11 | Sod Conseils Rech Applic | Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof |
| AR029489A1 (es) | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
| HK1056164B (en) | 2000-03-24 | 2013-06-21 | Euro-Celtique S.A. | Aryl-substituted pyrazole, triazole and tetrazole, and their uses |
| BR0109706A (pt) | 2000-03-31 | 2003-02-04 | Euro Celtique Sa | Aminopiridinas e seus usos como anticonvulsivantes e bloqueadores dos canais de sódio |
| FR2818978B1 (fr) * | 2000-12-28 | 2003-02-28 | Sod Conseils Rech Applic | Modulateurs de canaux sodiques derives de 2-piperidylimidazoles |
| TWI248438B (en) * | 2001-04-10 | 2006-02-01 | Sod Conseils Rech Applic | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
| FR2825926A1 (fr) * | 2001-06-14 | 2002-12-20 | Sod Conseils Rech Applic | Derives d'imidazoles modulant les canaux sodiques |
| CA2453633A1 (en) * | 2001-07-16 | 2003-01-30 | Euro-Celtique S.A. | Aryl substituted thiazolidinones and the use thereof |
| ATE317280T1 (de) | 2001-09-03 | 2006-02-15 | Newron Pharm Spa | Pharmazeutische zusammensetzung mit gabapentin oder deren analog und einem alpha-aminoamid und analgetische verwendung dieser zusammensetzung |
| AR036873A1 (es) * | 2001-09-07 | 2004-10-13 | Euro Celtique Sa | Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento |
| AR037233A1 (es) | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
| EP1478358B1 (en) | 2002-02-11 | 2013-07-03 | Bayer HealthCare LLC | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis |
| DE60328087D1 (de) * | 2002-03-13 | 2009-08-06 | Euro Celtique Sa | Aryl substituierte pyrimidine und deren verwendung |
| EP1532119A2 (en) * | 2002-07-31 | 2005-05-25 | Euro-Celtique S.A. | Aryl substituted benzimidazoles and their use as sodium channel blockers |
| EP1438956A1 (en) * | 2003-01-16 | 2004-07-21 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful as antimigraine agents |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| AR044503A1 (es) | 2003-03-18 | 2005-09-14 | Merck & Co Inc | Triazoles sustituidos con biarilo como bloqueantes del canal de sodio |
| DK1626714T3 (da) | 2003-05-20 | 2007-10-15 | Bayer Pharmaceuticals Corp | Dirarylurinstoffer mod sygdomme medieret af PDGFR |
| JP4198733B2 (ja) | 2003-07-22 | 2008-12-17 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 関連性障害の予防および処置に有用な、５−ｈｔ２ａセロトニンレセプターのモジュレーターとしてのジアリールおよびアリールへテロアリールウレア誘導体 |
| EA010485B1 (ru) | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты) |
| ES2629414T3 (es) * | 2003-12-26 | 2017-08-09 | Kyowa Hakko Kirin Co., Ltd. | Derivados de tiazol |
| EP1727803B3 (en) | 2004-03-23 | 2014-04-23 | Arena Pharmaceuticals, Inc. | Processes for preparing substituted n-aryl-n'-[3-(1h-pyrazol-5-yl)phenyl] ureas and intermediates thereof |
| US7183285B2 (en) * | 2004-04-29 | 2007-02-27 | Pharmix Corp. | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
| US20050282883A1 (en) * | 2004-04-29 | 2005-12-22 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
| US7199126B2 (en) * | 2004-04-29 | 2007-04-03 | Pharmix Corporation | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
| US20060084695A1 (en) * | 2004-04-29 | 2006-04-20 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
| US20050272770A1 (en) * | 2004-04-29 | 2005-12-08 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
| US7163945B2 (en) * | 2004-04-29 | 2007-01-16 | Pharmix Corp. | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
| SA05260357B1 (ar) | 2004-11-19 | 2008-09-08 | ارينا فارماسيتو تيكالز ، أنك | مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به |
| US20060111436A1 (en) * | 2004-11-23 | 2006-05-25 | John Griffin | Compositions and treatments for modulating kinase and/or HMG-CoA reductase |
| KR20060087386A (ko) * | 2005-01-28 | 2006-08-02 | 주식회사 대웅제약 | 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물 |
| JPWO2006137527A1 (ja) | 2005-06-23 | 2009-01-22 | 協和発酵キリン株式会社 | チアゾール誘導体 |
| PE20070182A1 (es) | 2005-07-29 | 2007-03-06 | Wyeth Corp | Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona |
| EP1924326B1 (en) | 2005-08-25 | 2016-10-12 | Steven Michael Weiss | Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow |
| US7855218B2 (en) | 2005-10-10 | 2010-12-21 | Convergence Pharmaceuticals Limited | Compounds |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| WO2007070760A2 (en) * | 2005-12-15 | 2007-06-21 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| EP1963280B1 (en) | 2005-12-22 | 2015-10-28 | Newron Pharmaceuticals S.p.A. | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators |
| AU2007254244C1 (en) | 2006-05-18 | 2014-07-31 | Arena Pharmaceuticals, Inc. | 3-pyrazolyl-benzamide-4-ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
| JP5406018B2 (ja) | 2006-05-18 | 2014-02-05 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ５−ｈｔ２ａセロトニンレセプターに関連する障害の処置に有用な５−ｈｔ２ａセロトニンレセプターのモジュレーターとしての１級アミン、およびその誘導体 |
| NZ571829A (en) | 2006-05-18 | 2011-10-28 | Arena Pharm Inc | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor |
| EP2081905B1 (en) * | 2006-07-28 | 2012-09-12 | Boehringer Ingelheim International GmbH | Sulfonyl compounds which modulate the cb2 receptor |
| EP2436750A3 (en) * | 2006-09-01 | 2014-08-20 | Pleotint, L.L.C. | Ligand exchange thermochromic, (LETC), systems |
| MX2009002888A (es) * | 2006-09-25 | 2009-03-31 | Boehringer Ingelheim Int | Compuestos que modulan el receptor cb2. |
| TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| EP1969934A1 (de) * | 2007-03-12 | 2008-09-17 | Bayer CropScience AG | 4-Cycloalkyl-oder 4-arylsubstituierte Phenoxyphenylamidine und deren Verwendung als Fungizide |
| JP2010529173A (ja) * | 2007-06-14 | 2010-08-26 | ハマースミス・イメイネット・リミテッド | 神経活性の測定 |
| US9567327B2 (en) | 2007-08-15 | 2017-02-14 | Arena Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
| WO2009061652A1 (en) * | 2007-11-07 | 2009-05-14 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| EP2326629B1 (en) * | 2008-07-10 | 2013-10-02 | Boehringer Ingelheim International GmbH | Sulfone compounds which modulate the cb2 receptor |
| NZ591111A (en) * | 2008-09-25 | 2013-08-30 | Boehringer Ingelheim Int | Sulfonyl compounds which selectively modulate the cb2 receptor |
| CN102264354B (zh) | 2008-10-28 | 2015-03-25 | 艾尼纳制药公司 | 用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物 |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| JP2012524761A (ja) | 2009-04-24 | 2012-10-18 | テイボテク・フアーマシユーチカルズ | ジアリールエーテル類 |
| US8299103B2 (en) * | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| US8383615B2 (en) | 2009-06-16 | 2013-02-26 | Boehringer Ingelheim International Gmbh | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor |
| TW201109335A (en) | 2009-08-04 | 2011-03-16 | Takeda Pharmaceutical | Heterocyclic compounds |
| EP2480544A1 (en) * | 2009-09-22 | 2012-08-01 | Boehringer Ingelheim International GmbH | Compounds which selectively modulate the cb2 receptor |
| US8993612B2 (en) * | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| WO2011075596A1 (en) | 2009-12-18 | 2011-06-23 | Arena Pharmaceuticals, Inc. | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| EP2523936A1 (en) | 2010-01-15 | 2012-11-21 | Boehringer Ingelheim International GmbH | Compounds which modulate the cb2 receptor |
| DE102010007281A1 (de) | 2010-02-08 | 2011-08-11 | EMC microcollections GmbH, 72070 | Neue Aminoalkyl-oxazol- und Aminoalkyl-thiazolcarbonsäureamide und ihre Anwendung zur Stimulation der endogenen situ Regeneration von Haarsinneszellen im Corti'schen Organ des Innenohres beim Säuger |
| WO2011109324A1 (en) | 2010-03-05 | 2011-09-09 | Boehringer Ingelheim International Gmbh | Tetrazole compounds which selectively modulate the cb2 receptor |
| EP2593434A1 (en) | 2010-07-16 | 2013-05-22 | Purdue Pharma LP | Pyridine compounds as sodium channel blockers |
| JP5746764B2 (ja) | 2010-07-22 | 2015-07-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節する化合物 |
| EP2616441B1 (en) | 2010-09-17 | 2019-08-07 | Purdue Pharma L.P. | Pyridine compounds and the uses thereof |
| AU2011311238A1 (en) | 2010-10-05 | 2013-04-04 | Purdue Pharma L.P. | Quinazoline compounds as sodium channel blockers |
| WO2012085650A1 (en) | 2010-12-22 | 2012-06-28 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
| PT2753606T (pt) | 2011-09-02 | 2017-10-02 | Purdue Pharma Lp | Pirimidinas como bloqueadoras dos canais de sódio |
| WO2013064883A1 (en) * | 2011-10-31 | 2013-05-10 | Purdue Pharma L.P. | Heteroaryl compounds as sodium channel blockers |
| AU2012321111A1 (en) | 2011-10-31 | 2013-05-16 | Purdue Pharma L.P. | Quaternized amines as sodium channel blockers |
| WO2013072758A1 (en) | 2011-11-15 | 2013-05-23 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
| RU2621734C1 (ru) | 2011-12-28 | 2017-06-07 | Янссен Сайенсиз Айрлэнд Юси | Гетеробициклические производные в качестве ингибиторов hcv |
| US9128307B2 (en) | 2012-02-20 | 2015-09-08 | Pleotint, L.L.C. | Enhanced thermochromic window which incorporates a film with multiple layers of alternating refractive index |
| US9206127B2 (en) | 2012-03-16 | 2015-12-08 | Purdue Pharm, L.P. | Substituted pyridines as sodium channel blockers |
| EP2844236B1 (en) | 2012-04-17 | 2018-12-19 | Purdue Pharma LP | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| US9714252B2 (en) | 2012-12-20 | 2017-07-25 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
| US9120786B2 (en) | 2013-03-04 | 2015-09-01 | Purdue Pharma, L.P. | Triazine carboxamides as sodium channel blockers |
| AU2014224310B2 (en) | 2013-03-04 | 2017-02-09 | Purdue Pharma L.P. | Pyrimidine carboxamides as sodium channel blockers |
| AU2014235063B2 (en) | 2013-03-15 | 2017-05-04 | Purdue Pharma L.P. | Carboxamide derivatives and use thereof |
| EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
| US9359330B2 (en) | 2013-08-26 | 2016-06-07 | Purdue Pharma L.P. | Substituted piperidines as sodium channel blockers |
| WO2015031036A1 (en) | 2013-08-26 | 2015-03-05 | Purdue Pharma L.P. | Azaspiro[4.5] decane derivatives and use thereof |
| US9828348B2 (en) | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
| US9340504B2 (en) | 2013-11-21 | 2016-05-17 | Purdue Pharma L.P. | Pyridine and piperidine derivatives as novel sodium channel blockers |
| WO2015094443A1 (en) | 2013-12-20 | 2015-06-25 | Purdue Pharma L.P. | Pyrimidines and use thereof |
| SG11201602787YA (en) | 2013-12-20 | 2016-07-28 | Novartis Ag | Heteroaryl butanoic acid derivatives as lta4h inhibitors |
| US9695144B2 (en) | 2013-12-23 | 2017-07-04 | Purdue Pharma L.P. | Dibenzazepine derivatives and use thereof |
| CA2934473C (en) | 2013-12-23 | 2019-08-20 | Purdue Pharma L.P. | Indazoles and use thereof |
| WO2015102682A1 (en) | 2013-12-30 | 2015-07-09 | Purdue Pharma L.P. | Pyridone-sulfone morphinan analogs as opioid receptor ligands |
| EP3097078B1 (en) | 2014-01-24 | 2022-05-25 | Purdue Pharma LP | Pyridines and pyrimidines and use thereof |
| WO2015123398A1 (en) | 2014-02-12 | 2015-08-20 | Purdue Pharma L.P. | Isoquinoline derivatives and use thereof |
| US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
| WO2015161011A1 (en) * | 2014-04-17 | 2015-10-22 | Merck Sharp & Dohme Corp. | Benzamide cgrp receptor antagonists |
| US9975854B2 (en) | 2014-05-06 | 2018-05-22 | Purdue Pharma L.P. | Benzomorphan analogs and use thereof |
| JP2017521488A (ja) | 2014-06-13 | 2017-08-03 | パーデュー、ファーマ、リミテッド、パートナーシップ | 複素環式モルフィナン誘導体及びその使用 |
| JP6360915B2 (ja) | 2014-06-13 | 2018-07-18 | パーデュー、ファーマ、リミテッド、パートナーシップ | アザモルフィナン誘導体及びその使用 |
| US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| ES2912881T3 (es) | 2014-12-23 | 2022-05-30 | Convergence Pharmaceuticals | Procedimiento para preparar derivados de alfa-carboxamida pirrolidina |
| WO2016201373A1 (en) | 2015-06-12 | 2016-12-15 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder |
| HK1247555A1 (zh) | 2015-07-15 | 2018-09-28 | Axovant Sciences Gmbh | 用於预防和治疗与神经变性疾病相关的幻觉的作为5-ht2a血清素受体的调节剂的二芳基脲和芳基杂芳基脲衍生物 |
| CN107118586A (zh) * | 2016-02-24 | 2017-09-01 | 中国科学技术大学 | 含氮杂环基取代的烯类化合物的用途 |
| MX388026B (es) * | 2016-03-11 | 2025-03-19 | Angel Pharmaceutical Co Ltd | Compuestos y métodos para modular la tirosina cinasa de bruton. |
| EP3573957B1 (en) | 2017-01-24 | 2023-04-26 | Rivara, Mirko | Compositions and methods for blocking sodium channels |
| EP3691634A4 (en) | 2017-10-05 | 2021-03-31 | Biogen Inc. | PROCESS FOR THE PREPARATION OF PYRROLIDINE ALPHA-CARBOXAMIDE DERIVATIVES |
| US10707913B2 (en) * | 2018-09-04 | 2020-07-07 | Raytheon Company | Composable transceiver using low bit count inputs and outputs |
| WO2020080534A1 (ja) * | 2018-10-18 | 2020-04-23 | 住友化学株式会社 | フェニルピラゾール化合物及び植物病害防除方法 |
| EP3870159B1 (en) * | 2018-10-26 | 2024-11-13 | University of South Florida | Drug for treating tinnitus |
| JP7325124B2 (ja) * | 2018-12-25 | 2023-08-14 | 学校法人東京理科大学 | ジャスモン酸内生促進剤及びジャスモン酸内生促進方法 |
| CN111825658B (zh) * | 2019-04-18 | 2024-11-08 | 华东理工大学 | Egfr三突变抑制剂及其应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ178996A (en) | 1974-11-15 | 1978-06-02 | Kornis G | Pyrfazole amides and thioamides;herbicidal compositions |
| JPS5975257A (ja) | 1982-10-23 | 1984-04-27 | Ricoh Co Ltd | 電子写真用感光体 |
| DE3307364A1 (de) * | 1983-03-02 | 1984-09-06 | Hoechst Ag, 6230 Frankfurt | Zweikomponenten-diazontypiematerial |
| DE3503773A1 (de) * | 1985-02-05 | 1986-08-07 | Basf Ag, 6700 Ludwigshafen | Thiazolylamide, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses |
| GB8624879D0 (en) * | 1986-10-17 | 1986-11-19 | May & Baker Ltd | Compositions of matter |
| US5015651A (en) * | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
| US5104960A (en) * | 1989-02-22 | 1992-04-14 | The Dow Chemical Company | Nucleophilic displacement method for synthesis of non-rigid PBZ polymers |
| HU217958B (hu) | 1989-06-30 | 2000-05-28 | E. I. Du Pont De Nemours And Co. | Helyettesített imidazolszármazékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
| PH27357A (en) * | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
| GB9005028D0 (en) | 1990-03-06 | 1990-05-02 | Sandoz Ltd | Improvements in or relating to organic compounds |
| JPH04164032A (ja) * | 1990-10-26 | 1992-06-09 | Mitsubishi Kasei Corp | 過酸化脂質生成抑制剤 |
| JPH05287563A (ja) | 1992-04-07 | 1993-11-02 | Hideaki Yamaguchi | 金属の表面処理方法 |
| KR950701317A (ko) | 1992-05-08 | 1995-03-23 | 오오쓰까 아끼히꼬 | 인돌 유도체(Indole Derivative) |
| JPH0725849A (ja) * | 1993-07-08 | 1995-01-27 | Nippon Soda Co Ltd | ２−トリフルオロメチルピロール誘導体および製造方法 |
| DE4325822A1 (de) * | 1993-07-31 | 1995-02-02 | Hoechst Ag | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| US5602156A (en) | 1993-09-17 | 1997-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | Method for inhibiting metalloproteinase expression |
| US5744492A (en) | 1993-09-17 | 1998-04-28 | United States Of America | Method for inhibiting angiogenesis |
| US6057346A (en) | 1994-12-12 | 2000-05-02 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of retroviral LTR promoters by calcium response modifiers |
| GB9503946D0 (en) * | 1995-02-28 | 1995-04-19 | Cancer Res Campaign Tech | Benzazole compounds |
| US5741818A (en) | 1995-06-07 | 1998-04-21 | University Of Saskatchewan | Semicarbazones having CNS activity and pharmaceutical preparations containing same |
| EP0795555A4 (en) * | 1995-09-28 | 1998-01-07 | Otsuka Pharma Co Ltd | ANALGESICS |
| JP2001510450A (ja) * | 1996-10-23 | 2001-07-31 | ザイモジェネティクス，インコーポレイテッド | 骨欠損状態を処置するための組成物および方法 |
| JP4039707B2 (ja) | 1996-12-03 | 2008-01-30 | 株式会社エス・ディー・エス バイオテック | 置換ピラゾール誘導体、その製造方法およびその誘導体を有効成分とする農園芸用殺菌剤 |
| US5925654A (en) | 1997-03-12 | 1999-07-20 | G.D. Searle & Co. | LTA4 , hydrolase inhibitors |
| AU7294098A (en) | 1997-05-09 | 1998-11-27 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| NZ501112A (en) | 1997-05-22 | 2002-10-25 | G | Substituted pyrazoles as p38 kinase inhibitors |
| TW450964B (en) * | 1997-08-29 | 2001-08-21 | Takeda Schering Plough Animal | Triazine derivatives, their production and use |
| US5942532A (en) | 1997-09-05 | 1999-08-24 | Ortho Pharmaceutical Corporation | 2-substituted phenyl-benzimidazole antibacterial agents |
| JP4385414B2 (ja) * | 1997-10-13 | 2009-12-16 | アステラス製薬株式会社 | アミド若しくはアミン誘導体 |
| US6271390B1 (en) * | 1998-05-22 | 2001-08-07 | Avanir Pharmaceuticals | Suppression of the IgE-dependent allergic response by benzimidazole analogs |
| JP2000109465A (ja) * | 1998-08-05 | 2000-04-18 | Nippon Soda Co Ltd | フェニルピラゾ―ル化合物、製法及び抗高脂血症薬 |
| TR200102277T2 (tr) * | 1998-11-06 | 2002-01-21 | Basf Aktiengesellschaft Ag. | Üç halkalı (Trisiklik) pirazol türevleri |
-
2000
- 2000-03-24 RU RU2001129155/04A patent/RU2001129155A/ru not_active Application Discontinuation
- 2000-03-24 KR KR1020017012292A patent/KR20020015308A/ko not_active Ceased
- 2000-03-24 AR ARP000101352A patent/AR023171A1/es unknown
- 2000-03-24 UA UA2001107227A patent/UA72244C2/uk unknown
- 2000-03-24 DK DK00919636.1T patent/DK1173169T3/da active
- 2000-03-24 AU AU40291/00A patent/AU782353B2/en not_active Ceased
- 2000-03-24 NZ NZ514756A patent/NZ514756A/en unknown
- 2000-03-24 CA CA002368631A patent/CA2368631A1/en not_active Abandoned
- 2000-03-24 EP EP00919636A patent/EP1173169B1/en not_active Expired - Lifetime
- 2000-03-24 TW TW089105616A patent/TW502019B/zh not_active IP Right Cessation
- 2000-03-24 CN CN00806810A patent/CN1353605A/zh active Pending
- 2000-03-24 YU YU68701A patent/YU68701A/sh unknown
- 2000-03-24 EP EP10004963.4A patent/EP2266960B1/en not_active Expired - Lifetime
- 2000-03-24 MX MXPA01009655A patent/MXPA01009655A/es not_active Application Discontinuation
- 2000-03-24 DE DE20080291U patent/DE20080291U1/de not_active Expired - Lifetime
- 2000-03-24 DE DE60044395T patent/DE60044395D1/de not_active Expired - Lifetime
- 2000-03-24 HU HU0201314A patent/HUP0201314A3/hu unknown
- 2000-03-24 BR BR0009322-0A patent/BR0009322A/pt not_active IP Right Cessation
- 2000-03-24 TR TR2001/02790T patent/TR200102790T2/xx unknown
- 2000-03-24 PT PT00919636T patent/PT1173169E/pt unknown
- 2000-03-24 WO PCT/US2000/007944 patent/WO2000057877A1/en not_active Ceased
- 2000-03-24 PL PL00351439A patent/PL351439A1/xx not_active Application Discontinuation
- 2000-03-24 IL IL14550800A patent/IL145508A0/xx unknown
- 2000-03-24 CZ CZ20013435A patent/CZ20013435A3/cs unknown
- 2000-03-24 JP JP2000607628A patent/JP4832647B2/ja not_active Expired - Fee Related
- 2000-03-24 US US09/533,864 patent/US6414011B1/en not_active Expired - Lifetime
- 2000-03-24 AT AT00919636T patent/ATE467620T1/de active
- 2000-03-24 ES ES00919636T patent/ES2345921T3/es not_active Expired - Lifetime
-
2001
- 2001-09-25 NO NO20014659A patent/NO20014659L/no not_active Application Discontinuation
- 2001-10-25 ZA ZA200108807A patent/ZA200108807B/en unknown
-
2002
- 2002-04-30 US US10/134,697 patent/US6737418B2/en not_active Expired - Lifetime
-
2003
- 2003-11-21 NZ NZ529690A patent/NZ529690A/en unknown
-
2010
- 2010-08-10 CY CY20101100744T patent/CY1111163T1/el unknown
- 2010-09-29 JP JP2010220062A patent/JP2011021028A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2001129155A (ru) | Соединения с арильными заместителями (варианты), фармацевтическая композиция и способ лечения расстройства, чувствительного к блокаде натриевых каналов у млекопитающего, способ лечения, профилактики различных заболеваний или уменьшения интенсивности гибели или потери нейронов (варианты), способ облегчения или предупреждения эпилептических припадков у животного (варианты), соединение - радиоактивный лиганд для участка связывания в натриевом канале | |
| JP2002540155A5 (enExample) | ||
| RU2002128916A (ru) | Арилзамещенные пиразолы, триазолы или тетразолы (варианты), фармацевтическая композиция, способ лечения заболевания, связанного с блокированием натриевых каналов, у млекопитающего, способ лечения, профилактики или снижения интенсивности различных нарушений или состояний, способ снижения интенсивности или профилактики приступов у животного | |
| RU2436780C2 (ru) | Производные 5-фенилтиазола и их применение в качестве ингибиторов рi3 киназы | |
| JP2019077725A5 (enExample) | ||
| RU2223116C2 (ru) | Применение производных арил (или гетероарил) азолилкарбинолов в приготовлении лекарственного средства для лечения нарушений, опосредованных избытком вещества p | |
| RU2017139727A (ru) | Гетероциклические ингибиторы erk1 и erk2 и их применение для лечения злокачественного новообразования | |
| JP2004520292A5 (enExample) | ||
| CA2565813A1 (en) | Substituted methyl aryl or heteroaryl amide compounds | |
| RU2003100516A (ru) | Производные сульфонилпирролипидина | |
| RU2003138074A (ru) | Замещенные 3-арил-5-арил-[1,2,4]-оксадиазолы и их аналоги в качестве активаторов каспаз и индукторов апоптоза, а также их применение | |
| JP2016504378A5 (enExample) | ||
| RU2006146608A (ru) | ОКТАГИДРОПИРРОЛО[3,4-с]-ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ АГЕНТОВ | |
| RU2481330C2 (ru) | Азотсодержащее ароматическое гетероциклическое соединение | |
| HRP20130143T1 (hr) | Derivati pirazolo piridina kao inhibitori nadph oksidaze | |
| JP2010533158A5 (enExample) | ||
| RU2009117705A (ru) | Производные 2-аминокарбонилпиридина | |
| RU2006100298A (ru) | Замещенные производные 3-алкил-и 3-алкенилазетидинов | |
| JP2006077019A5 (enExample) | ||
| IL160945A (en) | 4, 5 - diarylthiazole - 2 - carboxamides having cb1 - antagonistic, agonistic or partial agonistic activity and use thereof for the preparation of pharmaceutical compositions | |
| JP2008500284A5 (enExample) | ||
| RU2011116232A (ru) | Пиразолопиридиновые производные как ингибиторы надфн-оксидазы | |
| CA2409741A1 (en) | Tnf-.alpha. production inhibitors | |
| JP2019537603A5 (enExample) | ||
| RU2009131697A (ru) | Применение ингибитора trpm5 для регулирования секреции инсулина и гпп-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20060619 |